Urban Health Today Editors

Urban Health Today

<p class="p1">Andrew Hertler, MD, senior advisor and chief medical officer emeritus for <a href="http://evolent.com">Evolent</a>, discusses the FDA’s Oncologic Drugs Advisory Committee’s (ODAC) support of the FDA’s decision to restrict the use of PD-1 inhibitor drugs in first-line PD-L1-negative stomach and esophageal cancer.</p>


Rebecca Araujo

Study Highlights Need for Tailored Depression Interventions for Black Adolescents

Mental Health

Lou Portero

Transplant Line Skipping

Public Health

Annual Lung Cancer Screening: Engaging High-Risk Patients Improves Early Detection

Lung Cancer

Latest News

Dr. Andrew Hertler on The FDA Restricting PD-1 Inhibitor Use for PD-L1-Negative Stomach & Esophageal Cancers

Esophageal Cancer

Dr. Andrew Hertler discusses ODAC’s support of the FDA’s decision to restrict the use of PD-1 inhibitor drugs in first-line PD-L1-negative stomach and esophageal cancer.

Dr. Andrew Hertler on The FDA Restricting PD-1 Inhibitor Use for PD-L1-Negative Stomach &amp; Esophageal

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe